Introduction: Drug resistance has been the main obstacle in cancer therapy. A number of drug resistance-related molecules are under investigation but no one agent has already been used in clinical practice. The research on drug resistance-related microRNAs (miRNAs) may eventually lead to improved clinical strategies and outcomes for patients with esophageal cancer (EC).
Areas covered: This review summarizes the recent advances in drug resistance-related miRNAs in EC, and also analyzes the clinical and therapeutic applications they provide. The authors envisage future developments in the molecular mechanisms of these miRNAs and their potential applications to cancer treatment.
Expert opinion: Drug resistance-related miRNAs can be used as a useful therapeutic tool for EC. More investigations should be performed to promote the success of therapeutic-clinical use of miRNAs in cancer.